COMP <GO>
ABUS vs LXRX // GROSS PROFIT MARGIN
Arbutus Biopharma Corporation (NASDAQ) VS. Lexicon Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: ABUS 2
— LXRX 4
■ METRIC PARITY
LAST: $4.21 (-1.64%) • MKT CAP: $656.0M
gross-margins
—
LAST: $1.42 (-4.05%) • MKT CAP: $658.5M
gross-margins
96.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ABUS VS. LXRX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ABUS | LXRX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | — | 96.00% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -31.50% | -3.50 | LXRX | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -6.04% | -10.30% | +4.26 | ABUS | /fcf-yield <GO> |
| Operating Margin | -60.00% | -60.00% | 0.00 | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | -60.00% | 0.00 | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 128.20% | 180.00% | -51.80 | LXRX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.34 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 5/9 | -2.00 | LXRX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 44.2 | 36.0 | +8.20 | ABUS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $656.0M | $658.5M | -$2.5M | LXRX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ABUS REV | LXRX REV | ABUS GROSS % | LXRX GROSS % | ABUS FCF | LXRX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $14.1M | $49.8M | — | 98.0% | -$39.6M | -$67.9M |
| FY 2024 | $6.2M | $6.0M | — | 89.7% | -$65.0M | -$179.8M |
| FY 2023 | $18.1M | $1.1M | — | — | -$85.9M | -$161.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ABUS // BETA —
LXRX // BETA —